Poland: Medical and donor requirements in assisted reproduction
Editorial illustration only. It does not depict a verified clinic, official permit, real patient, or legal approval.
The short answer: separate medical clearance from legal permission
In Poland, medical and gamete-donor requirements for medically assisted reproduction come principally from the Act of 25 June 2015 on infertility treatment and the Health Minister’s health-requirements regulation. They mandate medical assessment, specified laboratory tests, consent and handling safeguards. They do not by themselves establish that a surrogacy arrangement is lawful, that a clinic accepts it, or that intended parents will be recognised as legal parents.
Check separately: (1) binding medical and donor rules; (2) the clinic’s protocol and programme criteria; and (3) the arrangement’s legal status, parentage and cross-border effects. Passing the first check does not replace the other two.
Which legal texts apply, and where the limits are
The main statute is the Act of 25 June 2015 on infertility treatment, covering gametes, embryos, consent, IVF and authorised assisted-reproduction centres. Detailed health-testing rules appear in the Health Minister’s regulation of 23 October 2015. Its consolidated text was published on 26 March 2025 as Dz.U. 2025, item 384 and incorporates amendments effective 24 July 2024.
The Act’s consolidated text directly was published in 2020 (Dz.U. 2020, item 442). This is a source-currentness limitation, not a claim that the Act was repealed.
How a doctor must assess a donor or recipient
Medical qualification is an individual decision, not a checklist. The regulation requires the doctor to consider the medical interview, available records, physical examination, required laboratory results and any additional tests indicated by the history or findings. The assessment covers current health, medical indications, collection or treatment risks, foreseeable effects on future health, and risks to the recipient and potential child.
The Act also requires medical grounds for collecting or using gametes and assessment of whether risks can be kept within acceptable limits. Donor and recipient health are assessed separately. The clinic should identify any unmet legal criterion, required further test or treatment, and whether the issue is a contraindication or a temporary delay.
Partner donation: required tests and a narrow direct-use exception
For partner donation, the regulation lists the following tests. For the first four infectious-disease tests shown (HIV, hepatitis B markers, hepatitis C antibodies and syphilis), a positive or unavailable result requires separate storage of the relevant material. That separate-storage note does not automatically extend to the conditional tests below; follow the specific conditions in the table.
| Test | Rule or qualification |
|---|---|
| HIV-1 and HIV-2 | Negative result; positive or unavailable result requires separate storage. |
| Hepatitis B markers: HBsAg and anti-HBc | Negative result; positive or unavailable result requires separate storage. |
| Hepatitis C antibodies (anti-HCV) | Negative result; positive or unavailable result requires separate storage. |
| Serological test for syphilis | Negative result; positive or unavailable result requires separate storage. |
| HTLV-I antibodies | Negative result; required for donors from high-prevalence areas, or where their sexual partner or parents come from such areas. |
| RhD antigen testing | Depends on information from the medical interview or health records. |
| Malaria, CMV and T. cruzi | Negative result; testing depends on travel, possible exposure and the characteristics of the donated cells. |
For partner donation not intended for direct use, the laboratory tests must be based on blood samples collected within the three months before the first gamete collection. If gametes are collected again from the same partner donor, a new blood sample must be collected no later than 24 months after the previous sample collection. For direct-use partner donation, the listed laboratory tests need not be performed. This narrow exception does not waive medical assessment, informed consent, documentation or other applicable safety rules.
Non-partner donation: broader donor screening
For non-partner donation, the schedule lists a negative result as the norm for HIV-1/2, hepatitis B markers (HBsAg and anti-HBc) and hepatitis C antibodies. It also requires a negative serological syphilis test and negative chlamydia NAT for male reproductive-cell donors.
HTLV-I testing is required in defined high-prevalence circumstances; where indicated, the listed norm is a negative result. RhD testing depends on medical history. Testing for malaria, CMV and Trypanosoma cruzi depends on travel, exposure and cell characteristics; the listed norm is negative when testing is indicated. The genetic-screening row lists a negative norm for screening known autosomal-recessive variants in the donor’s ethnic group and separately requires assessment of the risk of transmitting inherited diseases known in the family. These are regulatory requirements, not just an optional clinic package.
If assessment for non-partner donation identifies deviations from the donor’s normal health status, the doctor must state that collection is contraindicated. The effect of a specific result still depends on the applicable rule and clinical facts.
For non-partner donation, the Act requires donation to an anonymous recipient. When an embryo is created using non-partner-donor cells, the physician must also establish phenotypic similarity between donor and recipient from the available phenotype data. These are statutory requirements distinct from the laboratory schedule.
Timing, quarantine, genetic findings and conditional tests
For non-partner donation, laboratory testing requires a blood sample each time. The donated cells are subject to quarantine for at least 180 days, followed by repeat medical and laboratory testing. The rule is precise: after the 180-day quarantine, repeat medical and laboratory tests are generally required. If the donor’s blood sample was additionally tested by NAT for HIV, HBV and HCV, no additional blood sample is required; this NAT condition alone does not remove the repeat medical and laboratory examinations. Those repeat examinations are also not required if processing includes an inactivation step approved for the relevant viruses. The clinic should identify and document the exception it relies on; an internal policy alone is not enough.
Because these tests depend on exposure or history rather than applying universally, ask the clinic to record why each conditional test was or was not indicated.
The regulation includes screening for selected recessive variants and family-history risks. Article 3(2) of the Act separately prohibits restricting reproductive possibilities solely because a person carries a genetically determined disease. Do not assume every carrier result automatically disqualifies a donor: a clinician and Polish lawyer should assess the variant, risk and applicable rule.
Recipient health checks before transfer
The regulation has a separate testing schedule for a recipient of reproductive cells or embryos. It is not identical to the donor schedule.
| Recipient test | Legal note in the schedule |
|---|---|
| HIV-1/2 | If positive, antiretroviral therapy must be started and viral load reduced before transfer. |
| Hepatitis C antibodies (anti-HCV) | If positive, treatment is required before transfer. |
| Serological test for syphilis | If positive, treatment is required before transfer. |
| Toxoplasmosis | If infection is found, treatment is required before transfer. |
| Chlamydia | Negative result; testing by nucleic-acid amplification (NAT). |
| Cervical cytology | Included in the required schedule. |
| Vaginal cleanliness assessment | Included in the required schedule. |
| Rubella antibodies | The listed norm is positive; if negative, vaccination should be considered. |
A positive test does not always end treatment automatically: for several findings, the regulation expressly requires treatment before transfer. The doctor must assess contraindications and timing. Ask for a written health assessment and plan for abnormal results.
Informed consent, donor status and access to information
Consent is a legal condition. A non-partner donor must have full legal capacity and voluntarily give written consent before a doctor to collection and use of gametes, including uses specified by the Act. Before consenting, the donor must receive understandable information on the procedure, tests, risks, data protection and legal consequences, have an opportunity to ask questions, and confirm in writing that the medical-interview information is true to the best of their knowledge.
These capacity and written-consent requirements also apply to partner donors, and the recipient must likewise have full legal capacity. For non-partner donation, the donor’s written consent also covers posthumous use of the cells and embryo donation using embryos created from them. A donor’s consent can be withdrawn only before the applicable statutory cut-off: for direct use it must occur before the recipient procedure begins; for IVF, before embryo creation begins. The formal route depends on whether cells are used directly or stored in a bank.
Article 30 requires the non-partner donor to be informed about the statutory scope of donor information that the recipient and a person born through non-partner donation after reaching adulthood may access. Article 38(2) expressly gives that person, after adulthood, access to the donor’s year and place of birth and health information recorded in the register. Under Article 38(3), a legal representative of a minor may request donor health information only where the child’s treating doctor determines and records that it may help avert an immediate threat to the child’s life or health. These limited information rights do not grant access to the donor’s full identity. The clinic should explain the applicable access rules before consent is signed.
Under Polish law, partner donation means a male donor provides reproductive cells for use in a female recipient who is married to him or lives with him; cohabitation must be confirmed by matching declarations from both, and the recipient’s own reproductive cells are used. The consent and health requirements differ from non-partner donation, so the clinic should identify the route it applies and why.
When donor cells must not be used
Article 18 prohibits use of donor cells if the donor has withdrawn written consent, the recipient has not consented, or a medical contraindication exists. Cells collected for partner donation also cannot be used if that donor has died. For non-partner donation, cells cannot be used once ten children have already been born from previous use of that donor’s cells. This limit does not apply to partner-donation cells.
Article 18 also provides two specific routes to change the use category. Partner-donation cells may be used for non-partner donation if the donor gives written consent and a doctor assesses the medical basis. Cells collected for non-partner donation may be returned to that donor for partner-donation use if the donor withdraws consent to non-partner use in writing and gives written consent for partner use, subject to the applicable medical assessment. These are formal, case-specific routes, not automatic exceptions. The Act states these routes separately from the prohibition on use after a partner donor’s death; do not assume prior reclassification consent overrides that prohibition without Polish legal advice.
Article 33 separately permits transfer of embryos already created from partner-donation cells after the donor’s death. It expressly disapplies the Article 5(2) requirement to exhaust other infertility-treatment methods for at least 12 months. This does not authorise collecting new gametes from a deceased person; Article 24 separately prohibits collecting reproductive cells from a human corpse for assisted reproduction.
Written consent and medical conditions for embryo transfer
Article 20 requires the relevant written consents before the assisted-reproduction procedure begins, not merely immediately before transfer. For partner donation, the recipient and gamete donor consent to transfer. For non-partner donation, the recipient consents and, where she is married, her husband must consent; where she lives with a male partner, he must make the declaration required by the Family and Guardianship Code. For embryo donation, the embryo donors must give written consent to its transfer. A medical contraindication to transfer prevents transfer. If embryos created from partner-donation cells cannot be used directly and must be stored, Article 20(3) requires the relevant written transfer consent to be given again before each later assisted-reproduction procedure in which those stored embryos will be used.
Article 21 also prohibits transfer in specified circumstances, including withdrawal of the recipient’s consent and, where relevant, missing partner or donor consent. Required forms depend on embryo origin, who supplied the gametes and the recipient’s relationship status. Obtain the complete consent set before treatment and seek Polish legal review for unusual family or cross-border facts.
Where non-partner donation is used and the recipient lives with a male partner, the statutory declaration route carries a 14-month deadline: the cells or embryo must be used within 14 months after the declaration. Article 21(2) provides a narrow route for a guardianship court to authorise transfer where the recipient’s husband or the donor of partner-donation cells used to create the embryo has not consented. This remedy does not cure every consent defect or a medical contraindication.
The six-oocyte fertilisation limit is a statutory rule
Article 9(2) of the Act generally permits fertilisation of no more than six oocytes in an IVF procedure. A larger number may be fertilised if the recipient has reached age 35, if medical indications arise from a disease coexisting with infertility, or if two earlier IVF treatments were unsuccessful. The reason for fertilising more than six oocytes must be recorded in the medical documentation.
This is a statutory rule with express exceptions. If more than six oocytes are proposed, ask which exception applies and where it is recorded.
Separately, Article 5(2) generally permits IVF only after other infertility-treatment methods have been exhausted for at least 12 months. Treatment may begin sooner, or without exhausting those methods, if current medical knowledge indicates that they cannot result in pregnancy; the reason must be recorded in the medical documentation. This is a separate treatment prerequisite, not an exception to the six-oocyte limit.
How to distinguish law from clinic policy
The Act and regulation set the medical assessment, specified tests, consent, safe handling, quarantine and retesting rules, the ten-child limit for non-partner donor cells, the six-oocyte fertilisation limit and the permit framework for centres and gamete/embryo banks. Each requirement should be linked to a specific provision or table.
A clinic may apply stricter criteria under its own protocol, professional judgment, available services or a separate publicly funded programme. Examples include a clinic-specific donor age range, BMI or ovarian-reserve threshold, pregnancy or surgery history, smoking rules, extra genetic tests or psychosocial screening. These are examples, not asserted universal Polish legal requirements. Ask for the written protocol and whether each condition is law, a programme rule, case-specific medical judgment or clinic policy.
The provisions reviewed do not state one general numeric age ceiling for every gamete donor. The Act requires full legal capacity for non-partner donors, and the doctor assesses medical suitability. If a clinic claims Polish law sets a universal limit of 35 or another age, ask for the current provision. Article 9(2)’s age-35 threshold concerns the number of oocytes that may be fertilised, not donor age generally.
Documents and questions to request before committing
Before signing a programme agreement or paying a non-refundable fee, request documents that separate legal compliance from clinic-specific requirements:
- Authorisation: Centre and bank names/addresses, current Ministry of Health permit and public-register entry. A permit is generally required; the narrow exception covers collection for direct-use partner donation at a healthcare provider delivering inpatient, round-the-clock health services.
- Clinical protocol: donor and recipient test lists, reasons for conditional tests, sample dates, quarantine/retesting schedule and the provision supporting each exception.
- Medical decisions: written health assessments, a plan for abnormal results, and clear details of any contraindication or transfer delay.
- Consent: all donor, recipient, partner and embryo-donor forms, their legal effects, and how and when consent may be withdrawn.
- Limits and records: confirmation of the non-partner donor’s previous-use/ten-child check, planned oocyte count, documented basis for any exception to six, and records retained by the clinic.
- Policy classification: additional age, health, genetic or psychosocial criteria, each labelled as law, public-programme rule, medical judgment or clinic policy.
Keep test results, medical opinions, signed consents and the clinic’s written explanations. If it will not identify the legal basis for a claimed mandatory condition, pause and obtain independent Polish legal advice.
Practical conclusion
Treat Polish medical and donor rules as one compliance layer, not approval of the entire surrogacy plan. Verify the applicable legal version, classify each condition by source, confirm the donation route and recipient status, obtain medical assessments and consent documents, and check the centre’s authorisation. Separately obtain Polish advice on whether the proposed arrangement is legally available and how parentage would be established and recognised.
Recheck the legislation and current clinic protocol before relying on it.
